antisens
oligonucleotid
aso
short
synthet
dna
molecul
design
inhibit
translat
abstract
target
gene
protein
via
interact
messeng
rna
recent
small
interf
si
rna
develop
potent
tool
specif
inhibit
gene
express
aso
direct
signal
molecul
cytokin
receptor
transcript
factor
involv
allerg
immun
inflammatori
respons
appli
experiment
model
asthma
demonstr
potenti
therapeut
sever
asobas
drug
direct
oncogen
develop
therapi
lung
cancer
recent
reach
clinic
trial
aso
sirna
respiratori
syncyti
viru
infect
demonstr
good
potenti
treat
condit
particularli
combin
antivir
drug
although
asobas
therapeut
promis
lung
diseas
issu
specif
identif
correct
molecular
target
deliveri
carrier
system
well
potenti
advers
effect
must
care
evalu
clinic
applic
origin
idea
use
antisens
oligonucleotid
aso
principl
antisens
oligonucleotid
aso
mechan
action
relat
issu
specif
inhibit
gene
express
propos
year
ago
advantag
aso
therapeut
tool
immedi
aso
short
synthet
dna
molecul
design
interact
obviou
contrast
tradit
drug
design
inhibit
disbi
watsoncrick
basepair
mrna
encod
target
easerel
protein
alreadi
synthes
aso
prevent
translat
protein
singlestrand
dna
complementari
target
protein
interact
messeng
rna
howev
mrna
introduc
cell
bind
mrna
prevent
took
almost
year
develop
concept
first
translat
protein
approach
appear
straightforcurr
asobas
drug
clinic
use
fomivirsen
viward
initi
attempt
introduc
aso
cell
unsuccesstraven
cytomegaloviru
cmv
direct
aso
use
topi
oligonucleotid
larg
molecul
calli
treat
cmv
retin
sever
complic
aid
highli
neg
charg
penetr
cell
membran
present
asobas
drug
differ
phase
well
ii
oligonucleotid
easili
degrad
endoand
clinic
trial
hundr
develop
preexonucleas
bind
correspond
mrna
clinic
studi
despit
attract
antisens
concept
thu
critic
issu
develop
asobas
therapi
remain
sever
import
issu
relat
clinic
applicaof
respiratori
diseas
includ
tion
aso
review
discuss
problem
summar
target
select
aso
specif
publish
data
aso
strategi
respiratori
diseas
aso
stabil
emphas
recent
develop
futur
prospect
deliveri
aso
target
organcel
overcom
problem
oligonucleotid
degrad
recruit
despit
new
gener
aso
disadvantag
ensur
effici
cellular
deliveri
sever
chemic
modificacan
signific
thu
phosphorothioatemodifi
aso
tion
aso
develop
commonli
use
still
commonli
use
best
studi
phosphorothio
backbon
modif
figur
small
interf
rna
sinc
discoveri
natur
phenomenon
rna
aso
mechan
action
interfer
rnai
intens
studi
much
enthusiasm
potenti
new
power
therapeut
despit
intens
studi
mechan
aso
action
tool
specif
inhibit
gene
express
rnai
part
mrna
still
incomplet
understood
current
concept
suginn
antivir
defens
lower
eukaryot
induc
gest
major
mechan
action
phosphorothio
aso
doublestrand
ds
rna
process
nucleotid
activ
endonucleas
rnase
h
aso
bind
sirna
figur
rnai
result
degrad
homolog
mrna
result
mrna
degrad
prevent
translaendogen
mrna
complementari
antisens
strand
tion
specif
protein
aso
bind
mrna
also
prevent
sirna
although
transfect
mammalian
cell
dsrna
assembl
ribosom
complex
eg
via
steric
block
induc
strong
interferon
ifn
like
respons
eventu
lead
inhibit
rna
splice
figur
apoptosi
treatment
sirna
initi
rnai
without
caus
cell
death
sirna
promis
therapi
genet
ism
thu
specif
target
select
oncogen
phosphorothio
backbon
modif
repres
rerec
studi
demonstr
sirna
could
select
siplac
nonbridg
oxygen
sulfur
atom
lenc
diseaseassoci
allel
bear
singl
mismatch
phosphoru
figur
modif
commonli
refer
howev
clinic
applic
sirna
still
problemat
bea
firstgener
greatli
increas
resist
nucleas
caus
fulli
understand
mechan
rnai
action
howev
render
undesir
biolog
activ
aso
higher
eukaryot
exampl
exogen
appli
sirna
may
unrel
antisens
properti
see
section
interfer
endogen
rnai
pathway
induc
potenti
sever
antisens
formul
methyloligonucdanger
offtarget
effect
addit
difficult
leotid
morpholino
peptid
nucleic
acid
lock
nucleic
acid
ensur
effici
deliveri
cellular
uptak
sirna
compar
ribozym
recent
small
interf
si
rna
aso
doublestrand
sirna
bind
plasma
develop
improv
stabil
nucleprotein
rapidli
degrad
tissu
environ
although
ase
increas
bind
affin
mrna
howev
publish
report
sirna
use
vivo
model
lung
diseas
drawback
low
cell
penetr
lack
rnase
h
limit
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
infect
sirnabas
approach
inhibit
oncogen
express
proinflammatori
molecul
profibrot
target
lung
diseas
develop
correct
target
select
critic
develop
asobas
therapi
respiratori
diseas
target
molecul
must
import
diseas
pathogenesi
aso
extrem
potent
essenti
ensur
lung
diseas
specif
select
target
avoid
potenti
advers
effect
clinic
relev
target
protein
select
specif
aso
critic
issu
must
inhibit
express
target
gene
gene
similar
sequenc
ie
target
mrna
sequenc
homolog
gene
design
aso
genom
care
check
properti
dna
properti
provid
additionfor
possibl
hybrid
aso
sequenc
nontarget
al
therapeut
effect
exampl
cancer
howev
system
gene
sequenc
common
sever
molecul
releas
high
level
proinflammatori
cytokin
tumor
necrofamili
domain
express
mani
gene
must
avoid
selfsi
factor
tnf
interleukin
il
well
activacomplementari
region
four
contigu
guanin
resit
natur
killer
nk
cell
follow
applic
dnadu
region
rich
guanin
may
form
complex
aso
cation
lipid
complex
induc
advers
effect
novel
secondari
structur
prevent
effici
watsoncrick
hycation
cardiolipin
analogbas
liposom
appear
less
bridiz
target
mrna
avoid
toxic
effect
transfect
dna
sirna
presenc
immunostimulatori
cytosineguanin
phosphatein
vitro
vivo
compar
commerci
avail
link
dinucleotid
cpg
motif
within
aso
normal
undesirdotap
base
liabl
stimul
tolllik
receptor
tlr
sever
posom
cell
type
howev
instanc
may
includ
recent
year
new
carrier
polyethylenimin
pei
addit
benefici
effect
immun
system
develop
enhanc
effici
aso
deliveri
vitro
control
aso
specif
nonsens
mistarget
cell
vitro
vivo
despit
enhanc
deliveri
match
oligonucleotid
sequenc
import
assess
airway
epitheli
cell
pei
toxic
detriment
specif
hybrid
select
target
sequenc
lung
function
new
strategi
use
chitosandna
nanospher
intranas
deliveri
dna
recent
show
advantag
lipid
cation
carrier
nanospher
protect
dna
nucleas
degrad
multipl
compound
incorto
ensur
deliveri
aso
target
cell
cation
liposom
porat
nanospher
achiev
addit
effect
howar
often
use
complex
aso
intern
ever
deliveri
system
never
assess
antisens
pinocytosisendocytosi
liposom
deliveri
system
treatment
requir
studi
extens
use
intraven
local
applic
aso
airway
upon
system
applic
cancer
therapi
given
carrierrel
advers
effect
attract
method
asoliposom
complex
preferenti
enter
tumor
tissu
beaso
deliveri
lung
involv
use
natur
surfact
caus
increas
permeabl
blood
vessel
tumor
cation
properti
sever
studi
local
aso
applic
airway
reli
surfact
rather
use
howev
role
cation
lipid
aso
deliveri
artifici
carrier
system
recent
studi
singl
instillalimit
carrier
function
complex
dna
oligonucleot
sirna
mix
surfact
elastas
decreas
extid
cation
lipid
greatli
enhanc
immunostimulatori
nebul
enclos
chamber
three
consecut
day
prior
allergen
challeng
precis
dose
rat
receiv
determin
exposur
suppress
antigeninduc
airway
inflamm
follow
hour
exampl
demonstr
effect
aso
dose
durat
effect
depend
target
characterist
addit
import
effici
deliveri
system
quantiti
halflif
target
mrna
encod
protein
critic
determin
aso
pharmacokinet
pharmacodynam
vivo
applic
advers
effect
aso
therapi
tabl
result
hybrid
aso
nonspecif
sequenc
mrna
rather
target
sequenc
assess
express
target
gene
mrna
protein
level
follow
aso
treatment
import
confirm
specif
aso
effect
upon
dnarna
duplex
format
endonucleas
rnase
h
recruit
degrad
rna
duplex
result
gene
day
examin
potenti
sourc
nonsequencespecif
effect
aso
backbon
modif
oligonucleotid
aso
pharmacokinet
modifi
oligonucleotid
bind
famili
heparinbind
pharmacokinet
toxicolog
phosphorothio
protein
includ
growth
factor
receptor
exmodifi
aso
intens
studi
effect
dose
tracellular
matrix
protein
adhes
molecul
aso
vivo
applic
depend
effici
mechan
least
partial
explain
advers
effect
deliveri
system
mode
administr
system
versu
system
aso
applic
thrombocytopenia
hypotenloc
follow
system
applic
phosphorothio
oligos
protein
bind
due
polyanion
natur
nucleotid
bind
plasma
protein
ensur
prolong
oligonucleotid
also
respons
abil
effect
variou
aso
dose
system
intraven
subcuactiv
complement
outlin
section
immunostimutan
applic
human
care
evalu
sever
latori
cpg
motif
aso
sequenc
also
import
anticanc
therapi
trial
signific
toxic
observ
sourc
advers
effect
relat
system
cytokin
releas
clinic
relev
dose
fatigu
fever
flulik
syndrom
sirna
also
exert
nontargetrel
biolog
effect
particular
induct
pharmacokinet
properti
aerosol
aso
studproinflammatori
cytokin
effect
relat
abil
i
sever
anim
model
follow
aso
deliveri
lung
dsrna
bind
tlr
present
immun
cell
induc
limit
system
distribut
detect
local
deliveri
cellular
activ
must
care
assess
aso
airway
allow
administr
lower
dose
comsequ
use
pare
intraven
therapi
lung
diseas
studi
phosphorothio
aso
type
adenosin
receptor
local
deliveri
aso
offer
advantag
system
intra
singl
effect
inhal
dose
venou
applic
allow
lower
dose
use
durat
effect
lung
day
studi
thu
minim
system
toxic
import
consider
aso
spleen
tyrosin
kinas
syk
use
aso
airway
adenosin
releas
oligonucleotid
degrad
product
activ
adenosin
construct
stemloop
structur
contain
three
receptor
induc
bronchoconstrict
adenosin
receptor
phosphorothio
modif
deliv
aerosolizaar
upregul
certain
clinic
condit
particularli
asthtion
vivo
use
syk
asoliposom
complex
combin
target
studi
aso
cation
liposom
treatment
experiment
asthma
see
section
dotap
neutral
carrier
lipid
dioleoylphosphatidylethaanoth
sourc
potenti
advers
effect
relat
aso
nolamin
dope
treatment
rat
nebul
syk
asodeliveri
system
discuss
section
enhanc
immunosliposom
complex
inhibit
syk
mrna
protein
express
timulatori
properti
aso
appli
cation
liposom
comin
alveolar
macrophag
plex
may
releas
proinflammatori
cytokin
studi
effect
aerosol
syk
asoliposom
liposom
may
affect
cellular
function
directli
eg
inhibit
complex
two
model
infecti
model
airway
tnfinduc
endotheli
vascular
cell
adhes
exinflamm
induc
helminth
nippostrongylu
brasilienpress
cytotox
cation
liposom
dosedepend
si
ii
igemedi
allerg
inflamm
induc
requir
care
evalu
liposom
use
ovalbumin
sensit
brown
norway
rat
model
allerg
asthma
syk
aso
significantli
inhibit
inflammatori
cell
antisens
treatment
lung
diseas
tration
airway
lung
eosinophilia
rise
tnf
bronchoalveolar
lavag
induc
antigen
challeng
syk
aso
also
suppress
antigeninduc
tracheal
contract
also
aerosol
sirna
syk
rat
ovalbuminina
asthma
complex
heterogen
diseas
major
chalduc
asthma
obtain
promis
downregul
inflamleng
identifi
appropri
molecular
target
aso
mation
unpublish
observ
thu
aerosol
syk
aso
identifi
deliveri
system
target
lung
minim
sysinhibit
mani
central
compon
allerg
asthma
inflamtem
distribut
relat
advers
effect
sever
mation
exampl
approach
experiment
model
although
syk
promis
molecular
target
aso
therapi
asthma
inflammatori
condit
acut
lung
injuri
studi
need
assess
potenti
risk
relat
tyrosin
kinas
syk
mediat
earli
signal
event
imsyk
inhibit
exampl
recent
studi
implic
syk
portant
pathophysiolog
allerg
asthma
initi
tumor
suppressor
gene
breast
gastric
cancer
additioncrosslink
high
affin
receptor
ige
mast
cell
basophil
bp
aso
direct
syk
gene
alli
establish
syk
abundantli
express
lung
epitheli
cell
involv
product
proinscript
factor
essenti
develop
reflammatori
molecul
thu
syk
aso
may
adspons
also
reduc
lung
inflamm
ahr
vantag
shortterm
local
therapi
sever
lung
condit
recent
studi
signal
transduc
activ
transcript
eg
acut
respiratori
distress
syndrom
longterm
applic
stat
target
use
intranas
applic
decoy
olisyk
aso
rais
potenti
safeti
issu
must
gonucleotid
mous
model
ovalbumininduc
asthma
assess
studi
demonstr
inhibit
antigeninduc
airway
inflamm
hyperreact
anoth
signal
molecul
potenti
target
aso
therapi
asthma
lyn
srcfamili
kinas
lyn
phosphoto
directli
target
bronchial
smooth
muscl
contract
asthryl
occur
immedi
result
conform
chang
aso
develop
administ
aerosol
cytoplasm
domain
allergenmedi
crossform
rabbit
signific
reduct
broncholink
lyn
interact
syk
induc
activaconstrict
airway
inflamm
asobas
therapi
tion
eosinophil
lyn
associ
receptor
current
phase
ii
clinic
trial
subunit
import
differenti
bone
marrow
stem
cell
vitro
studi
demonstr
aso
appli
phosphorothioatemodifi
stem
cell
although
lyn
aso
never
appli
oligonucleotid
liposom
deliveri
system
nake
dna
experiment
model
asthma
import
lyn
eosihowev
altern
approach
recent
develop
nophil
differenti
vivo
confirm
lyn
knockout
includ
adenoviralmedi
express
aso
mice
mrna
ca
depend
chlorid
channel
bronchial
epithelium
ovalbuminsensit
mice
approach
decreas
ahr
mucu
product
use
recombin
recent
studi
allerg
asthma
attempt
inhibit
intracelladenoviru
aso
deliveri
target
cell
offer
advanular
pathway
involv
inflammatori
cell
activ
inhal
tage
method
select
airway
epithelium
aso
mitogenactiv
protein
kinas
downand
prolong
express
transfect
gene
week
follow
regul
ovalbumininduc
pulmonari
eosinophilia
mucu
instil
howev
adenovirusmedi
gene
deliveri
hypersecret
airway
hyperrespons
ahr
muinduc
immun
respons
adenoviru
preclud
repeat
rine
model
asthma
aso
subunit
transcripappl
sever
safeti
concern
tion
factor
rela
regul
express
proinpotenti
oncogen
transform
flammatori
gene
appli
intraven
significantli
inhibit
importantli
anim
model
asthma
aso
variou
target
allerg
respons
mous
model
despit
proof
molecul
appli
prior
antigen
challeng
whether
principl
studi
system
applic
aso
asomedi
target
molecul
involv
asthma
seem
feasibl
treatment
asthma
given
crucial
involvepathogenesi
also
effici
ongo
allerg
inflam
transcript
factor
regul
immun
remat
requir
studi
spons
recent
ribozym
target
human
receptor
chain
given
import
role
helper
type
cytokin
also
known
develop
approach
receptor
allerg
asthma
target
aso
offer
advantag
tradit
antisens
mechtherapi
exampl
aso
appli
intraven
anism
action
ribozym
reli
activ
rnase
p
murin
model
asthma
inhibit
eosinophilia
ahr
ubiquit
present
cell
construct
recycl
allakhverdi
colleagu
use
intratrach
inject
aso
induc
complementari
mrna
cleavag
therefor
common
chain
granulocytemacrophag
appear
act
effici
dnabas
antisens
colonystimul
factor
gmcsf
receptor
demonstr
anoth
recent
studi
use
sirna
silenc
gene
express
signific
reduct
eosinophilia
ahr
rat
model
transcript
regul
cytokin
vitroasthma
move
forward
clinic
test
intranas
appli
sirna
downregul
protein
express
well
applic
aso
stem
cell
factor
kit
ligand
kitlg
eotaxin
product
human
bronchial
epiessenti
develop
mast
cell
decreas
lung
thelial
cell
inflamm
murin
model
asthma
aso
transtudi
genet
asthma
identifi
sever
potenvestig
regard
effici
effect
potenti
tial
asthma
suscept
gene
inflammatori
mediaadvers
effect
tor
disintegrin
metalloproteas
domain
adwhen
infus
intraven
aso
prepar
show
g
proteincoupl
receptor
asthma
susceptibil
dosedepend
system
toxic
thrombocytopenia
iti
gpra
may
new
target
antisens
therapi
flulik
syndrom
hypotens
asthenia
clinic
although
biochem
mechan
link
mani
canditri
asobas
therapeut
combin
chemotherad
gene
asthma
pathogenesi
poorli
understood
aso
peutic
agent
strategi
also
need
extens
studi
unforstrategi
may
help
elucid
pathway
tunat
publish
report
local
applic
aso
lung
cancer
lung
cancer
mani
oncogen
identifi
antisens
strategi
intend
specif
cleav
genom
studi
target
antisens
therapi
sever
asobas
drug
rna
rsv
recent
develop
applic
reach
phase
iiiii
trial
anticip
aso
link
tetraadenyl
shown
recruit
soon
approv
clinic
use
see
stahel
zangemeistercellular
nucleas
rnasel
success
inhibit
rsv
replicawittk
review
particular
antiapoptot
protein
tion
importantli
combin
subtherapeut
dose
promis
target
aso
therapi
nonsmal
cell
aso
antivir
drug
ribavirin
demonstr
potent
inhiblung
cancer
aso
direct
gene
induc
itori
effect
recent
studi
describ
use
sirna
rsv
apoptosi
cancer
cell
potenti
effect
chemothervivo
mice
treat
intranas
sirna
nanoparticl
rsv
api
protein
infect
rsv
show
substanoth
molecular
target
aso
therapi
lung
cancer
includ
tialli
decreas
viru
titer
lung
decreas
inflamm
signal
transduct
molecul
protein
kinas
prkca
airway
hyperreact
compar
control
anim
regulatori
subunit
protein
kinas
inhibit
rsv
piv
follow
intranas
instil
raf
kinas
protein
encod
hra
sirna
mous
also
demonstr
addit
recent
oncogen
numer
preclin
studi
focus
target
vitro
studi
show
abil
sirna
inhibit
replic
regul
apoptosi
cell
cycl
progress
angiogenesi
newli
discov
coronaviru
sarscov
caus
metastasi
apoptosi
suppressor
survivin
agent
sever
acut
respiratori
syndrom
sar
cytochrom
c
oxidas
assembl
protein
begin
potenti
import
research
area
sever
growth
factor
receptor
receptor
tyrosin
tie
develop
innov
aso
therapi
infecti
diseas
kinas
well
transcript
factor
asobas
drug
lung
tabl
ii
clinic
trial
lung
cancer
short
oligonucleotid
sequenc
phosphorothio
backbon
modif
conclus
centli
lock
nucleic
acidmodifi
oligonucleotid
bispecif
activ
bclxl
anoth
antiapoptot
aso
promis
therapeut
tool
variou
respiratori
bcl
protein
develop
show
enhanc
antitumor
diseas
rang
infect
asthma
lung
cancer
fibrosi
activ
cancer
cell
acut
respiratori
distress
syndrom
major
advantag
aso
convent
drug
capac
specif
sinc
human
cancer
cell
line
preserv
rnai
machineri
block
synthesi
diseaseassoci
protein
thu
prevent
use
sirna
silenc
oncogen
involv
cancer
pathogeneparticip
pathogenesi
si
suggest
inde
sirna
sphase
kinaseassoci
protein
molecul
involv
cell
cycl
aso
highli
potent
specif
therefor
regul
overexpress
variou
cancer
includ
essenti
correct
molecular
target
identifi
therapi
smallcel
lung
carcinoma
appli
use
lentivir
adeappli
aso
complex
heterogen
diseas
asthma
novir
vector
strategi
significantli
inhibit
tumor
growth
present
major
challeng
sinc
condit
involv
sever
vitro
vivo
although
sever
vitro
studi
pathway
numer
gene
poorli
understood
geneenvironus
sirna
variou
target
molecul
potenti
import
ment
interact
approach
specif
target
critic
tumorigenesi
sirnabas
strategi
requir
inmolecul
asthma
success
develop
asobas
drug
clinic
applic
anticip
system
applic
minim
therapeut
dose
thu
reduc
system
advers
effect
near
futur
genet
asthma
rapidli
develop
field
import
discoveri
suscept
gene
importher
sever
critic
challeng
develop
asobas
therapeut
addit
select
correct
tant
gene
target
antisens
therapi
may
provid
target
protein
specif
aso
effect
essenti
inhibian
import
contribut
treatment
common
diseas
tion
gene
must
avoid
sequencespecif
eg
aso
therapi
also
potenti
becom
power
tool
cpgmediat
sequencenonspecif
phosphorothioatemeagainst
lung
cancer
success
anticip
base
intens
diat
advers
effect
care
assess
new
formulamolecular
studi
discoveri
causal
oncogen
lung
tion
aso
sirna
promis
therapeut
cancer
base
publish
observ
target
deliveri
applic
requir
studi
mechan
action
safeti
new
methodolog
deliveri
aso
select
target
aso
lung
feasibl
signific
advantag
